Patent Assignment
Reel/Frame 043267/0165
Change of Name
Recorded: 2017-07-20
Pages: 7
Assignor
RANA THERAPEUTICS, INC.
Executed: 2017-06-26
Assignee
TRANSLATE BIO, INC.
200 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(82)
Delivery of Mrna for the Augmentation of Proteins and Enzymes in Human Genetic Diseases
Application:
12/957,340 →
Publication:
US 2011/0244026
Mrna for Use in Treatment of Human Genetic Diseases
Liver Specific Delivery of Messenger Rna
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
Application:
14/124,608 →
Publication:
US 2014/0206753
Cleavable Lipids
Cftr Mrna Compositions and Related Methods and Uses
Mrna Therapy for Fabry Disease
Pulmonary Delivery of Mrna
Mrna Therapy for Urea Cycle Disorders
Application:
14/309,387 →
Publication:
US 2014/0294940
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
Ionizable Cationic Lipids
Lipid-Derived Neutral Nanoparticles
Nuclease Resistant Polynucleotides and Uses Thereof
Application:
14/406,424 →
Publication:
US 2015/0267192
Pulmonary Delivery of Mrna to Non-Lung Target Cells
Lipid Formulations for Delivery of Messenger Rna
Cns Delivery of Mrna and Uses Thereof
Application:
14/521,168 →
Publication:
US 2015/0110857
Mrna Therapy for Phenylketonuria
Mrna Therapy for Argininosuccinate Synthetase Deficiency
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
Application:
14/650,104 →
Publication:
US 2015/0366997
Methods for Purification of Messenger Rna
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
Application:
14/774,263 →
Publication:
US 2016/0184458
Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations
Methods and Compositions for Delivering Mrna Coded Antibodies
Quantitative Assessment for Cap Efficiency of Messenger Rna
Quantitative Assessment for Cap Efficiency of Messenger Rna
Methods for Purification of Messenger Rna
Ribonucleic Acids with 4'-Thio-Modified Nucleotides and Related Methods
Encapsulation of Messenger Rna
Cftr Mrna Compositions and Related Methods and Uses
Messenger Rna Based Viral Production
Application:
14/898,071 →
Publication:
US 2016/0122727
Messenger Rna Therapy for Treatment of Articular Disease
Mrna Therapy for Pompe Disease
Liver Specific Delivery of Messenger Rna
Mrna Therapy for the Treatment of Ocular Diseases
Application:
15/128,303 →
Publication:
US 2017/0143848
Modification of Rna-Related Enzymes for Enhanced Production
Biodegradable Lipids for Delivery of Nucleic Acids
Mrna Therapy for Phenylketonuria
Ionizable Cationic Lipids
Delivery of Mrna for the Augmentation of Proteins and Enzymes in Human Genetic Diseases
Application:
61/265,653 →
Mrna for Use in Treatment of Human Genetic Diseases
Application:
61/418,389 →
Cleavable Lipids
Application:
61/494,745 →
Compositions and Methods for Mrna Delivery
Application:
61/494,881 →
Lyophilized Liposomal Formulations
Application:
61/494,882 →
Ionizable Cationic Lipids
Application:
61/617,468 →
Modified Drug Encapsulated Liposomal Compositions and Related Methods of Use
Application:
61/617,478 →
Pulmonary Delivery of mRNA to Non-Lung Target Cells
Application:
61/657,452 →
Nuclease Resistant Polynucleotides and Related Methods
Application:
61/657,465 →
Compositions and Methods for Mrna Delivery
Application:
61/734,753 →
Cftr Mrna Compositions and Related Methods and Uses
Application:
61/783,663 →
Quantitative Assessment for Cap Efficiency of Messenger Rna
Application:
61/784,253 →
Quantitative Assessment for Cap Efficiency of Messenger Rna
Application:
61/784,337 →
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
Application:
61/784,766 →
Methods and Compositions for Delivering Mrna Coded Antibodies
Application:
61/784,903 →
Methods for Purification of Messenger Rna
Application:
61/784,996 →
Ribonucleic Acids with 4'-Thio-Modified Nucleotides and Related Methods
Application:
61/785,098 →
Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations
Application:
61/789,375 →
Messenger Rna Based Viral Production
Application:
61/834,512 →
Cns Delivery of Mrna and Uses Thereof
Application:
61/894,246 →
Mrna Therapy for Argininosuccinate Synthetase Deficiency
Application:
61/894,294 →
Lipid Formulations for Delivery of Messenger Rna
Application:
61/894,299 →
Mrna Therapy for Phenylketonuria
Application:
61/894,303 →
Methods and Compositions for Delivering Mrna Coded Antibodies
Application:
61/920,165 →
Lipid Formulations for Delivery of Messenger Rna
Application:
61/953,516 →
Messenger RNA Therapy for the Treatement of Ocular Diseases
Application:
61/969,483 →
Methods for Purification of Messenger Rna
Application:
61/984,503 →
Biodegradable Lipids for Delivery of Nucleic Acids
Application:
62/005,266 →
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
Application:
62/016,512 →
Cns Delivery of Mrna and Uses Thereof
Application:
62/020,161 →
Encapsulation of Messenger Rna
Application:
62/020,163 →
Mrna Therapy for Treatment of Articular Disease
Application:
62/088,141 →
Mrna Therapy for Pompe Disease
Application:
62/135,338 →
Modification of Rna-Related Enzymes for Enhanced Production
Application:
62/241,350 →
Multimeric Coding Nucleic Acid and Uses Thereof
Application:
62/320,073 →
Messenger RNA Therapy for the Treatment of Ornithine Transcarbamylase Deficiency
Application:
62/349,331 →
Novel Lipid Nanoparticle Formulations of Mrna
Application:
62/420,413 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application:
62/420,421 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application:
62/420,428 →
Novel Formulations for Subcutaneous Delivery of Nucleic Acids
Application:
62/420,435 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application:
62/421,007 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application:
62/421,021 →
Related Assignments
(24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 16, 2011
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES
Reel/Frame 025966/0743 →
Assignment of Assignor's Interest
Feb 14, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 032220/0341 →
Assignment of Assignor's Interest
Mar 28, 2014
From: GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL; DEROSA, FRANK; ZHANG, JERRY CHI
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 032551/0705 →
Assignment of Assignor's Interest
Jul 30, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033424/0593 →
Assignment of Assignor's Interest
Aug 14, 2014
From: RUDOLPH, CARSTEN; PLANK, CHRISTIAN
To: ETHRIS GMBH
Reel/Frame 033534/0692 →
Assignment of Assignor's Interest
Aug 14, 2014
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK; SMITH, LIANNE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033534/0676 →
Assignment of Assignor's Interest
Sep 9, 2014
From: GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033699/0668 →
Assignment of Assignor's Interest
Sep 18, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033768/0260 →
Assignment of Assignor's Interest
Sep 18, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033773/0920 →
Assignment of Assignor's Interest
Oct 16, 2014
From: DEROSA, FRANK; GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033963/0353 →
Assignment of Assignor's Interest
Oct 20, 2014
From: DEROSA, FRANK; GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033981/0806 →
Assignment of Assignor's Interest
Nov 19, 2014
From: DEROSA, FRANK; HEARTLEIN, MICHAEL; KARVE, SHRIRANG
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 034213/0634 →
Assignment of Assignor's Interest
Dec 4, 2014
From: DEROSA, FRANK; HEARTLEIN, MICHAEL; DIAS, ANUSHA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 034375/0009 →
Assignment of Assignor's Interest
Dec 19, 2014
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 034554/0896 →
Assignment of Assignor's Interest
Jan 22, 2015
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; SMITH, LIANNE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 034802/0125 →
Assignment of Assignor's Interest
Feb 24, 2015
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035014/0049 →
Assignment of Assignor's Interest
Apr 21, 2015
From: HEARTLEIN, MICHAEL; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035454/0892 →
Assignment of Assignor's Interest
Apr 21, 2015
From: ANDERSON, DANIEL; DONG, YIZHOU
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 035454/0912 →
Assignment of Assignor's Interest
Jun 5, 2015
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035833/0462 →
Confirmatory License
Dec 1, 2015
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037176/0046 →
Assignment of Assignor's Interest
Jan 29, 2016
From: RUDOLPH, CARSTEN; PLANK, CHRISTIAN
To: ETHRIS GMBH
Reel/Frame 037619/0861 →
Assignment of Assignor's Interest
Apr 6, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 042177/0032 →
Assignment of Assignor's Interest
Jan 24, 2018
From: DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 044721/0775 →
Assignment of Assignor's Interest
Feb 10, 2021
From: GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL; DEROSA, FRANK; ZHANG, JERRY CHI
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 055213/0294 →